Celularity inks biomaterials commercialization partnership and exclusive license, expects up to $35 million in non-dilutive payments
- Celularity is realigning operations to focus on longevity therapeutics following the biomaterials partnership and license announcement.
- Celularity will retain manufacturing revenues as part of the strategic commercialization partnership for its biomaterials portfolio.
No comments:
Post a Comment
Note: Only a member of this blog may post a comment.